With the FDA approval of oral Wegovy (semaglutide 25 mg tablet), patients now have a genuine choice: take a daily pill or stick with the weekly injection. Both contain the same active ingredient — semaglutide — and both are FDA-approved for chronic weight management. But the practical differences are significant. This guide compares the two formulations head-to-head using data from the OASIS 4 trial (oral) and the STEP 1 trial (injectable) to help you make an informed decision.
Same Active Ingredient, Different Delivery
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system pathways. Whether delivered as a daily oral tablet or a weekly subcutaneous injection, the pharmacological mechanism is identical. The difference lies entirely in how the drug reaches your bloodstream — and the lifestyle adjustments each route requires.
Weight Loss Efficacy: What the Trials Show
No direct head-to-head trial has compared oral Wegovy 25 mg to injectable Wegovy 2.4 mg. However, indirect comparison of the two pivotal trials shows comparable results:
- OASIS 4 (oral semaglutide 25 mg): Participants achieved a mean weight loss of approximately 13–15% over 68 weeks.
- STEP 1 (injectable semaglutide 2.4 mg): Participants achieved a mean weight loss of approximately 14.9% over 68 weeks.
Both trials enrolled adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and included lifestyle intervention components. The weight-loss results are statistically similar, suggesting that the pill is comparably effective to the injection for most patients.
Key Differences in Daily Life
While efficacy is comparable, the two formulations differ substantially in how they fit into your routine:
- Dosing frequency: The oral tablet is taken once daily. The injection is administered once weekly.
- Empty stomach requirement: The pill must be taken on an empty stomach with ≤4 oz of plain water, followed by a 30-minute fast. The injection has no food restrictions.
- Titration timeline: The oral form titrates from 1.5 mg to 25 mg over 4 months. The injectable titrates from 0.25 mg to 2.4 mg over 16–20 weeks.
- Storage: The pill can be stored at room temperature (≤30°C). The injection must be refrigerated (2–8°C) until first use, then can be kept at room temperature for up to 28 days.
- Needles: The pill requires no needles. The injection uses a pre-filled pen with a fine-gauge needle.
Convenience Trade-Offs
The pill eliminates the need for needles, sharps disposal, and refrigeration — major advantages for patients with needle phobia or those who travel frequently. However, the strict 30-minute morning fasting window is a real lifestyle constraint. You cannot have coffee, tea, juice, or any other beverage or food during this period. For many patients, this is more disruptive than a weekly injection that takes 30 seconds and has no dietary restrictions.
The injection's once-weekly schedule is easier to remember for some patients and eliminates the risk of daily non-adherence. However, it requires injection technique training and access to refrigeration for storage.
Wegovy Pill vs Injection: Full Comparison Table
| Feature | Oral Wegovy (Pill) | Injectable Wegovy (Shot) |
|---|---|---|
| Active Ingredient | Semaglutide (25 mg tablet) | Semaglutide (2.4 mg injection) |
| Frequency | Once daily | Once weekly |
| Route | Oral (swallow whole) | Subcutaneous injection |
| Weight Loss (Trials) | ~13–15% (OASIS 4) | ~14.9% (STEP 1) |
| Titration Period | 4 months (1.5 mg → 25 mg) | 16–20 weeks (0.25 mg → 2.4 mg) |
| Food Restrictions | Strict: 30-min fast before dose | None |
| Storage | Room temperature | Refrigerated (2–8°C) |
| Cost Range (Monthly) | $149–$249 (self-pay) | $130–$220 (self-pay) |
| Needle Required? | No | Yes |
Who Should Choose Pill vs Injection?
Consider these factors when deciding:
- Choose the pill if: You are needle-phobic, prefer not to refrigerate medication, travel frequently, or want the simplicity of a daily oral routine and can commit to the 30-minute fasting window.
- Choose the injection if: You have busy or unpredictable mornings, prefer once-weekly dosing, have a history of GI issues that may worsen with oral semaglutide, or struggle with daily medication adherence.
- Consider switching if: You have been on one form for 3+ months and are experiencing tolerability issues, lifestyle conflicts, or cost differences that favor the other formulation.
How to Switch Between Pill and Injection
If you are switching from injectable to oral Wegovy, your provider will typically advise you to:
- Wait one week after your last injection before starting the oral tablet
- Begin the oral tablet at the 1.5 mg starting dose and follow the full titration schedule
- Never overlap doses — taking both forms simultaneously increases the risk of severe GI side effects and hypoglycemia
Switching from oral to injectable follows a similar approach: stop the pill and start the injection at 0.25 mg the following week. Always consult your provider before making any changes.
Oral GLP-1 tablets now available — from $99/mo
Compare oral GLP-1 options including Wegovy pills and Foundayo. MEDVi offers tablets alongside injectables — a provider helps you choose.
See Oral GLP-1 Options →Medical Disclaimer
Wegovy is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Common side effects include nausea, vomiting, diarrhea, and constipation. Always consult your healthcare provider before starting or switching weight-loss medications. Individual results may vary.